Full name
The DESTINY Study: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Depemokimab in Adults With Hypereosinophilic Syndrome (HES)
NCT Number
NCT05334368
Geography
US
Non-US
Locations
Argentina, Australia, Belgium, Brazil, China, Czechia, Denmark, Germany, Greece, Hong Kong, Israel, Italy, Japan, Mexico, Poland, Romania, South Korea, Spain, United Kingdom, United States
Primary Endpoints
Frequency of HES flares. Up to 52 weeks
Order
2
Disease
Version
Phase
3
Status
Recruiting